WANY
TGTX icon

Wealthspire Advisors (New York)’s TG Therapeutics TGTX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-754
Closed -$27.2K – 2717
2025
Q3 		$27.2K Buy
+754
New +$24.8K ﹤0.01% 1512
2021
Q4 		– Sell
-14,913
Closed -$496K – 622
2021
Q3 		$496K Buy
+14,913
New +$461K 0.01% 356

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Wealthspire Advisors (New York)'s TGTX Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 754 shares — an estimated $27.2K sold.

Wealthspire Advisors (New York) first reported a position in TGTX in Q3 2021 and held it in 2 quarters. The position peaked at $496K in Q3 2021. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 754 TG Therapeutics shares in Q4 2025, an estimated $27.2K.
  • Wealthspire Advisors (New York) first reported a position in TG Therapeutics in Q3 2021 and held it in 2 quarters.
  • Wealthspire Advisors (New York)'s TG Therapeutics position peaked at $496K in Q3 2021.
  • 351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.